Altimmune (ALT) Price & Analysis

Compare

3,430 Followers

ALT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.90 - $11.16

Previous CloseN/A

Volume1.55M

Average Volume (3M)5.15M

Market Cap

$279.82M

Enterprise Value$229.46M

Total Cash (Recent Filing)$149.83M

Total Debt (Recent Filing)$1.59M

Price to Earnings (P/E)―

Beta2.03

Next Earnings

Nov 11, 2025

EPS Estimate

-0.33

Last Dividend Ex-Date

Feb 06, 2017

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding81,106,970

10 Day Avg. Volume2,546,982

30 Day Avg. Volume5,148,597

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.82

Enterprise Value/Revenue11.47K

Enterprise Value/Gross Profit-5.60K

Enterprise Value/Ebitda-2.53

Forecast

1Y Price Target

$19.22

Price Target Upside468.64% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPemvidutide reached its primary endpoint of statistically significant MASH resolution and showed strong trends in fibrosis improvement, making it a promising treatment for MASH.

Drug EfficacyAI-based analysis revealed statistically significant fibrosis resolution, supporting the efficacy of the drug.

Market PotentialEvidence demonstrating that Pemvi did not raise HbA1c should broaden its addressable market, especially among diabetic patients.

Bears Say

Clinical Development ChallengesALT will rely on a partner or additional funding to execute against these development priorities.

Clinical Trial ResultsPemvidutide missed on 1-point improvement in fibrosis, causing the stock to trade down ~50%, as investors were expecting significant results on both co-primary endpoints.

Stock PerformanceThe stock is recommended at a Sell rating with a significant downside to the price target.

Altimmune News

Altimmune reports Q2 EPS (27c), consensus (32c)

Reports Q2 revenue $5,000 vs $5,000 last year. “Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss...

7h ago

ALT

Options Volatility and Implied Earnings Moves Today, August 12, 2025

Today, several major companies are expected to report earnings: Inovio Pharmaceuticals (INO), Altimmune (ALT), Sea (SE), Luminar Technologies...

7h ago

ALT

Altimmune board of directors appoint Jerry Durso as Chairman

Altimmune (ALT) announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025....

1d ago

ALT

Options Volatility and Implied Earnings Moves This Week, August 11 – August 14, 2025

This week, several major companies will be reporting earnings. Among them are Plug Power (PLUG), Cisco Systems (CSCO),...

1d ago

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Precigen (PGEN) 2.42% +1.44,...

25d ago

ALT

Altimmune’s Pemvidutide Faces Uncertainty Amid MASH Market Challenges and Pending Developments

William Blair analyst Andy Hsieh has reiterated their neutral stance on ALT stock, giving a Hold rating on...

1h ago

ALT

Altimmune Faces Legal Storm as Trial Results Disappoint

Altimmune, Inc., a biopharmaceutical company, is facing a class action lawsuit following a significant setback in its IMPACT...

6d ago

ALT

ALT Earnings this Week: How Will it Perform?

Altimmune (ALT) is scheduled to report 2nd quarter earnings on 08/07/2025. Regarding Q2 estimates, Wall Street analysts expect...

7d ago

ALT

Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment

Altimmune (($ALT)) announced an update on their ongoing clinical study. Altimmune, Inc. is currently conducting the RESTORE TRIAL,...

1M ago

ALT

Altimmune price target lowered to $15 from $25 at Citizens JMP

Citizens JMP lowered the firm’s price target on Altimmune (ALT) to $15 from $25 and keeps an Outperform...

1M ago

ALT

Altimmune resumed with a Sell at Goldman Sachs

Goldman Sachs resumed coverage of Altimmune (ALT) with a Sell rating and $1 price target representing 79% downside....

1M ago

ALT

Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development

Altimmune (ALT) has received a new Sell rating, initiated by Goldman Sachs analyst, Corinne Johnson. Corinne Johnson has...

1M ago

ALT

Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment

Altimmune (($ALT)) announced an update on their ongoing clinical study. Altimmune, Inc. is currently recruiting for the RESTORE...

1M ago

ALT

Altimmune enrolls first patient in Restore Phase 2 trial

Altimmune (ALT) announced that it has enrolled the first patient in the Restore Phase 2 trial evaluating the...

1M ago

ALT

ALT FAQ

What was Altimmune Inc’s price range in the past 12 months?

Altimmune Inc lowest stock price was $2.90 and its highest was $11.16 in the past 12 months.

What is Altimmune Inc’s market cap?

Altimmune Inc’s market cap is $279.82M.

When is Altimmune Inc’s upcoming earnings report date?

Altimmune Inc’s upcoming earnings report date is Nov 11, 2025 which is in 91 days.

How were Altimmune Inc’s earnings last quarter?

Altimmune Inc released its earnings results on Aug 12, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.336 by $0.066.

Is Altimmune Inc overvalued?

According to Wall Street analysts Altimmune Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Altimmune Inc pay dividends?

Altimmune Inc pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here

What is Altimmune Inc’s EPS estimate?

Altimmune Inc’s EPS estimate is -0.33.

How many shares outstanding does Altimmune Inc have?

Altimmune Inc has 81,106,970 shares outstanding.

What happened to Altimmune Inc’s price movement after its last earnings report?

Altimmune Inc reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.336. Following the earnings report the stock price went down -4.16%.

Which hedge fund is a major shareholder of Altimmune Inc?

Currently, no hedge funds are holding shares in ALT

Altimmune Stock Smart Score

Neutral

Fundamentals

Return on Equity

-57.28%

Trailing 12-Months

Asset Growth

-16.51%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Altimmune Inc

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of infectious diseases, liver diseases, and cancer. The company is primarily engaged in creating intranasal and oral therapies that aim to stimulate immune responses without the need for injections. Its core products include ALT-801, an immunotherapeutic for obesity and metabolic disease, and a range of other candidates targeting hepatitis B and various cancers.

Altimmune (ALT) Earnings & Revenues

Historic Earnings Reports

ALT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted the anticipation for the IMPACT Phase 2b NASH trial results and financial strategies to support development. The expansion into AUD and ALD also shows growth potential. However, net losses and R&D expenses remain concerns.View all ALT earnings summaries

ALT Stock 12 Month Forecast

Average Price Target

$19.22

▲(468.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","16":"$16","29":"$29","9.5":"$9.5","22.5":"$22.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,9.5,16,22.5,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.23,6.058461538461539,7.886923076923077,9.715384615384615,11.543846153846154,13.372307692307693,15.20076923076923,17.029230769230768,18.857692307692307,20.686153846153847,22.514615384615386,24.34307692307692,26.17153846153846,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.23,5.383076923076923,6.536153846153846,7.689230769230769,8.842307692307692,9.995384615384616,11.148461538461538,12.30153846153846,13.454615384615384,14.607692307692307,15.76076923076923,16.91384615384615,18.066923076923075,{"y":19.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.23,4.212307692307693,4.194615384615385,4.176923076923077,4.15923076923077,4.141538461538461,4.123846153846154,4.1061538461538465,4.088461538461539,4.070769230769231,4.053076923076923,4.035384615384616,4.0176923076923075,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >